

Male or female individuals (age ≥ 18 years) with ESKD, receiving hemodialysis, treated with ESA or without side effects to ESA treatment

Randomization

4000 IU/week iv. EPO alfa or beta or equivalent doses of any other ESA

18000 IU/week iv. EPO alfa or beta or equivalent doses of any other ESA

Assessment of clinical outcomes (composite of major cardiovascular events, cardiovascular mortality, safety of treatments), quality of life, and costs

Assessment of clinical outcomes (composite of major cardiovascular events, cardiovascular mortality, safety of treatments), quality of life, and costs